Royalty Pharma plc (RPRX) and Cytokinetics (CYTK) Announce Expanded Strategic Funding Collaboration

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. SPCX
2. SBUX
3. LEVI
4. NVDA
5. GOOGL
6. ORCL
7. USO
8. STZ
9. CRGY
10. AAPL

Go back to Royalty Pharma plc (RPRX) and Cytokinetics (CYTK) Announce Expanded Strategic Funding Collaboration

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

May 22, 2024 4:10 PM EDT

Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise

NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the companys expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.

We are... More